×
About 272,352 results

ALLMedicine™ Insulin Center

Research & Reviews  130,871 results

Role of ceramides in the pathogenesis of diabetes mellitus and its complications.
https://doi.org/10.1016/j.jdiacomp.2020.107734
Journal of Diabetes and Its Complications; Mandal N, Grambergs R et. al.

Dec 3rd, 2020 - Diabetes mellitus (DM) is a systemic metabolic disease that affects 463 million adults worldwide and is a leading cause of cardiovascular disease, blindness, nephropathy, peripheral neuropathy, and lower-limb amputation. Lipids have long been reco...

Anti-diabetic effects of astaxanthin on an STZ-induced diabetic model in rats.
https://doi.org/10.1507/endocrj.EJ20-0699
Endocrine Journal; Zhuge F, Ni Y et. al.

Dec 3rd, 2020 - Type 2 diabetes mellitus (T2DM), which is characterized by insulin resistance and relative insulin insufficiency, has become the most common chronic metabolic disease threatening global health. The preferred therapies for T2DM include lifestyle in...

Hybrid Closed-loop therapy: Where are we in 2021?
https://doi.org/10.1111/dom.14273
Diabetes, Obesity & Metabolism; Leelarathna L, Choudhary P et. al.

Dec 3rd, 2020 - Hybrid closed-loop systems are characterised by the coexistence of algorithm driven automated insulin delivery combined with manual mealtime boluses. Used correctly, these insulin delivery systems offer better glucose control and reduced risk of h...

Mechanism Of Action Of Imeglimin - A Novel Therapeutic Agent For Type 2 Diabetes.
https://doi.org/10.1111/dom.14277
Diabetes, Obesity & Metabolism; Hallakou-Bozec S, Vial G et. al.

Dec 3rd, 2020 - Imeglimin is an investigational first-in-class novel oral agent for the treatment of Type 2 diabetes (T2D). Several pivotal Phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favorable ...

Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of d...
https://doi.org/10.1042/CS20201029
Clinical Science (London, England : 1979); Ryan MJ

Dec 3rd, 2020 - Incretins represent a group of gut-derived peptide hormones that, at physiological concentrations, potentiate the release of insulin. Work leading to the discovery of incretins began as early as the late 1800s where scientists, including Claude Be...

see more →

Guidelines  157 results

ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID...
https://doi.org/10.1111/pedi.13118
Pediatric Diabetes REFERENCES; Priyambada L, Wolfsdorf JI et. al.

Sep 16th, 2020 - The International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guideline 2018 for management of diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state provide comprehensive guidance for management of DKA ...

Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30057-7
Cell Metabolism; Dalenberg JR,et al

Mar 2nd, 2020 - There is a general consensus that overconsumption of sugar-sweetened beverages contributes to the prevalence of obesity and related comorbidities such as type 2 diabetes (T2D). Whether a similar relationship exists for no- or low-calorie “diet” dr...

Personal aging markers and ageotypes revealed by deep longitudinal profiling
https://www.nature.com/articles/s41591-019-0719-5
Nature Medicine; Ahadi S,et al

Jan 12th, 2020 - The molecular changes that occur with aging are not well understood. Here, we performed longitudinal and deep multiomics profiling of 106 healthy individuals from 29 to 75 years of age and examined how different types of ‘omic’ measurements, inclu...

Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B,et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical...

Comparison of salivary nitric oxide and oral health in diabetic patients with and without xerostomia
https://www.sciencedirect.com/science/article/pii/S1871402119305752?via%3Dihub
Diabetes & Metabolic Syndrome; Abadi PA,et al

Nov 24th, 2019 - Diabetes mellitus (DM) is a chronic multi-systemic metabolic disorder; diabetic patients are more prone to xerostomia and oral health problems than others. There are evidences that nitric oxide (NO) plays an important role in healthy salivary glan...

see more →

Drugs  343 results see all →

Clinicaltrials.gov  135,237 results

Role of ceramides in the pathogenesis of diabetes mellitus and its complications.
https://doi.org/10.1016/j.jdiacomp.2020.107734
Journal of Diabetes and Its Complications; Mandal N, Grambergs R et. al.

Dec 3rd, 2020 - Diabetes mellitus (DM) is a systemic metabolic disease that affects 463 million adults worldwide and is a leading cause of cardiovascular disease, blindness, nephropathy, peripheral neuropathy, and lower-limb amputation. Lipids have long been reco...

Anti-diabetic effects of astaxanthin on an STZ-induced diabetic model in rats.
https://doi.org/10.1507/endocrj.EJ20-0699
Endocrine Journal; Zhuge F, Ni Y et. al.

Dec 3rd, 2020 - Type 2 diabetes mellitus (T2DM), which is characterized by insulin resistance and relative insulin insufficiency, has become the most common chronic metabolic disease threatening global health. The preferred therapies for T2DM include lifestyle in...

Hybrid Closed-loop therapy: Where are we in 2021?
https://doi.org/10.1111/dom.14273
Diabetes, Obesity & Metabolism; Leelarathna L, Choudhary P et. al.

Dec 3rd, 2020 - Hybrid closed-loop systems are characterised by the coexistence of algorithm driven automated insulin delivery combined with manual mealtime boluses. Used correctly, these insulin delivery systems offer better glucose control and reduced risk of h...

Mechanism Of Action Of Imeglimin - A Novel Therapeutic Agent For Type 2 Diabetes.
https://doi.org/10.1111/dom.14277
Diabetes, Obesity & Metabolism; Hallakou-Bozec S, Vial G et. al.

Dec 3rd, 2020 - Imeglimin is an investigational first-in-class novel oral agent for the treatment of Type 2 diabetes (T2D). Several pivotal Phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favorable ...

Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of d...
https://doi.org/10.1042/CS20201029
Clinical Science (London, England : 1979); Ryan MJ

Dec 3rd, 2020 - Incretins represent a group of gut-derived peptide hormones that, at physiological concentrations, potentiate the release of insulin. Work leading to the discovery of incretins began as early as the late 1800s where scientists, including Claude Be...

see more →

News  5,629 results

New Study Pinpoints How Mediterranean Diet Reduces Diabetes Risk
https://www.medscape.com/viewarticle/941649

Nov 25th, 2020 - The known reduction in the risk of type 2 diabetes associated with adoption of the Mediterranean diet appears specifically attributed to its beneficial effects on some key factors, a new study published online in JAMA Network Open reveals. While a...

Metformin Improves Most Outcomes for T2D During Pregnancy
https://www.medscape.com/viewarticle/941337

Nov 19th, 2020 - Women with type 2 diabetes who take metformin during pregnancy to control their blood glucose levels experience a range of benefits, including reduced weight gain, reduced insulin doses, and fewer large for gestational age babies, suggest the resu...

Golimumab Preserves Insulin Production in Type 1 Diabetes
https://www.medscape.com/viewarticle/941224

Nov 17th, 2020 - The human monoclonal antibody golimumab (Simponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year, newly published phase 2 data indicate. Results from the...

Huge Variations in Access Holding Back T1D Tech Adoption
https://www.staging.medscape.com/viewarticle/941101

Nov 16th, 2020 - Increased adoption of the latest technologies to manage type 1 diabetes is being held back by a lack of knowledge of the benefits among clinicians in certain areas of England and Wales, leading to wide variations in access, say UK experts. They ar...

Huge Variations in Access Holding Back T1D Tech Adoption
https://www.medscape.com/viewarticle/941101

Nov 16th, 2020 - Increased adoption of the latest technologies to manage type 1 diabetes is being held back by a lack of knowledge of the benefits among clinicians in certain areas of England and Wales, leading to wide variations in access, say UK experts. They ar...

see more →

Patient Education  115 results see all →